Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

<div>Comparison of FGF21 changes between patients with or without a significant relative decrease of liver fat content. (a) Patients without a significant relative decrease liver fat content (&lt;29%); (b) patients with a significant relative decrease liver fat content (≥29%).</div>

Journal of Diabetes Research

fig3

Figure 3

Figure 3: Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease 

Figure 3 | Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease 